Memorial Sloan Kettering Cancer Center Updates on the DORA Trial

Feb 16, 2019 | Cancer Clinical Trials, Prostate Cancer

URO Today included an update on the DORA trial, which is an open-label investigator-initiated phase III study sponsored by Memorial Sloan Kettering Cancer Center and managed by the Prostate Cancer Clinical Trials Consortium. Follow the link below to learn more about this important prostate cancer trial. The investigators are targeting 738 patients with a completion target of 2023. The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.

Lead Research/Investigator

Michael Morris, MD.  


Pin It on Pinterest